Magical Trade
Tuesday, March 21, 2023
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Magical Trade
No Result
View All Result
Home Trade News

Pfizer CEO says chances are ‘very high’ FDA will approve low-dose Covid shots for kids under 5

by
February 8, 2022
in Trade News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

What happens during a ‘credit crunch’ — and how you can prepare for one

Russia and China are being driven together as the chasm with the West deepens

Pfizer CEO Albert Bourla on Tuesday said he believes the Food and Drug Administration will authorize the company’s Covid vaccine for children under 5 years old under a fast-track process that allows the agency to review the data as soon as researchers compile it in real time.

“I think the chances are very high for FDA to approve it,” Bourla told CNBC’s Meg Tirrell, while noting that the regulatory process still has to play out. “I think that they will be pleased with the data and they will approve,” he said.

Data on Pfizer and BionTech‘s vaccine for kids under 5 years old is expected on Friday when briefing documents for the FDA’s vaccine advisory committee are published. The committee has a meeting scheduled for Feb. 15 to discuss the shots for young kids.

Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.
John Thys | AFP | Getty Images

Pfizer and BioNTech asked the FDA last week to expand the authorization for their vaccine to most kids under 5. The FDA had asked the companies to start submitting data for authorization of the first two-doses of the three-dose vaccine for children six months through 4-years-old.

Pfizer and BioNTech expect kids under 5 will ultimately need three doses for the highest level of protection against the omicron Covid variant and future strains of the virus. The companies said data on the third dose will be finished and submitted to the FDA in the coming months.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

WHO says omicron BA.2 subvariant will rise globally, but it’s unclear if it can reinfect people

Pfizer CEO says chances are ‘very high’ FDA will approve low-dose Covid shots for kids under 5

Johnson & Johnson plant pauses Covid vaccine production, report says

Pfizer expects $54 billion in 2022 sales on Covid vaccine and treatment pill

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer

Moderna’s Covid vaccine for teens awaits OK as regulators review heart inflammation risk

Merck expects to sell $5 billion to $6 billion of its new Covid treatment pill in 2022

These countries have the lowest Covid vaccination rates in the world

Pfizer amended its clinical trial for younger kids in December to study a third shot after the first two doses did not produce an adequate immune response in children 2- to 4-years-old. Younger kids will receive a smaller, three microgram dose compared with the 30 microgram shots that are approved for adults.

Children under 5-years-old are the last age group left in the U.S. that isn’t eligible for vaccination. There has been growing public pressure from many parents and doctors for the FDA to speed up authorization of the vaccine as the omicron variant has lead to an increase in children hospitalized with Covid.

Pfizer and BioNTech said last week that their application for emergency approval came in response to an “urgent public health need” for younger children as omicron has caused an unprecedented wave of infection across the country.

White House chief medical advisor Dr. Anthony Fauci said last month that he expects the vaccine to receive FDA authorization in February.

ShareTweetPin

Related Posts

What happens during a ‘credit crunch’ — and how you can prepare for one

by
March 21, 2023
0

Tetra Images | Tetra Images | Getty Images The recent banking crisis has fueled concern of a "credit crunch" and...

Russia and China are being driven together as the chasm with the West deepens

by
March 21, 2023
0

Chinese President Xi Jinping speaks with Russian President Vladimir Putin as leaders gather for a family photo during the Belt...

Dodge resurrects controversial Challenger SRT Demon for final year of V8 muscle cars

by
March 21, 2023
0

In this article STLA Follow your favorite stocksCREATE FREE ACCOUNT 2023 Dodge Challenger SRT Demon 170 Dodge DETROIT -- Dodge...

Goldman’s Oppenheimer says stocks will stay ‘fat and flat’ — and reveals how to trade it

by
March 21, 2023
0

A potential crisis in the global banking sector may have been averted over the weekend, as Swiss authorities stepped in...

Meta can rally more than 25% thanks to Reels and efficiency plans, Morgan Stanley says

by
March 21, 2023
0

Meta 's tightening its belt and has business improvements that may not be fully appreciated, Morgan Stanley said. Analyst Brian...

Next Post

Chipotle shares rise on better-than-expected earnings, CEO says chain is 'fortunate' it can raise prices

Apple's acquisition history shows why a Peloton buy is out of the question

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Fund manager believes FAANG is dead — says now it’s all about MANTA

    0 shares
    Share 0 Tweet 0
  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Bank of America names its top global tech stocks — including one it says has upside of 100%

    0 shares
    Share 0 Tweet 0
  • Josh Brown says Nvidia’s potential is ‘scary’ ahead of a potential AI boom

    0 shares
    Share 0 Tweet 0
  • This idiot-proof portfolio has beaten traditional stocks and bonds over 50 years

    0 shares
    Share 0 Tweet 0
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.magicaltrade.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.magicaltrade.net